Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Semaglutide

Ozempic, Rybelsus, Wegovy

Bibliografia - Quali fonti bibliografiche per Semaglutide?

  1. ACCORD study Group, NEJM, 2011, 364 (9), 818.

  2. Agenzia Italiana del Farmaco − AIFA, Ozempic − Riassunto Caratteristiche di Prodotto, 2024, 17 aprile https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home (accesso: maggio 2024).

  3. Agenzia Italiana del Farmaco − AIFA, Wegony − Riassunto Caratteristiche di Prodotto, 2024a, 17 aprile https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home (accesso: maggio 2024).

  4. Agenzia Italiana del Farmaco − AIFA, Rybelsus − Riassunto Caratteristiche di Prodotto, 2024b, 16 aprile https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home (accesso: maggio 2024).

  5. Ahmann A.J. et al., Diabetes Care, 2018, 41 (2), 258 (studio clinic SUSTAIN 3).

  6. Ahrén B.et al., Lancet Diabetes Endocrinol., 2017, 5 (5), 341 (Studio clinic SUSTAIN 2).

  7. Al refaie A. et al., Calcif, Tissue Int.2024, 12, doi: 10.1007/s00223−024−01240−1.

  8. Aldhaleei W.A. et al., Pharmaceutical. (Basel), 2024, 17 (2), 199.

  9. Alorfi N.M., Algarni A.S., Clin. Pharmacol., 2022, 14, 61.

  10. American Diabetes Association − ADA, Diabetes Care, 2021, 44 (Suppl. 1), S111.

  11. American Diabetes Association − ADA, Symposium disentangles perception from reality regarding potential adverse effects of GLP−1 RAs, 2024, June 24 https://www.adameetingnews.org/symposium−disentangles−perception−from−reality−regarding−potential−adverse−effects−of−glp−1−ras/ (accesso: luglio 2024).

  12. Andersen A. et al., Drugs, 2021, 81, 1003.

  13. Andersen E. et al., Hum. Reprod., 2022, 37 (7), 1414.

  14. Antza C. et al., Drug Des. Devel. Ther., 2019, 13, 2985.

  15. Apperloo E.M. et al., Lancet Diabetes Endocrinol., 2024, 12 (8), 545.

  16. Ard J. et al., Adv. Ther., 2021, 38 (6), 2821.

  17. Aroda V.R. et al., Lancet Diabetes Endocrinol., 2017, 5 (5), 355 (studio clinico SUSTAIN 4).

  18. Aroda V.R. et al., Diabetes Care, 2019, 42 (9), 1724 (studio clinic PIONEER 1).

  19. Aroda V.R. et al., Diabetes Metab., 2019a, 45 (5), 409.

  20. Barkmeier A.J. et al., Ophthalmol. Retina., 2024, DOI: 10.1016/j.oret.2024.05.003.

  21. Bækdal T.A. et al., J. Clin. Pharmacol., 2018, 58 (10), 1314.

  22. Bækdal T.A. et al., Expert. Opin. Drug Metab. Toxicol., 2018a, 14 (8), 869.

  23. Bækdal T.A. et al., Clin. Pharmacokinet., 2019, 58 (9), 1193.

  24. Bækdal T.A. et al., Diabetes Ther., 2021, 12, 1915.

  25. Benn M. et al., Diabetologia, 2021, 64, 1492.

  26. Bezin J. et al., Diabetes Care, 2023, 46 (2), 384.

  27. Bikou A. et al., Expert. Opin. Pharmacother., 2024, 25 (5), 611.

  28. Bliddal H. et al., World Congress on Osteoarthritis (OARSI), 2024, 18−21 April, Vienna (Poster) https://sciencehub.novonordisk.com/congresses/eco2024/Bliddal.html (accesso: luglio 2024).

  29. Blundell J. et al., Diabetes Obes. Metab., 2017, 19 (9), 1242.

  30. Buckley S.T. et al., Sci. Transl. Med., 2018, 10 (467), eaar7047.

  31. Butler et al., Lancet 2024, 403 (10437), 1635.

  32. Capehorn M.S. et al., Diabetes Metab., 2020, 46 (2), 100 (studio clinic SUSTAIN 10).

  33. Carlsson Petri K.C. al., Diabetes, 2018, 9 (4), 1533.

  34. Caruso I et al., Metabolis., 2020, 109, 154272.

  35. Cesta C.E. et al., JAMA Intern. Med., 2023, 184 (2), 144.

  36. Cosentino F. et al., Eur. Heart J., 2020, 41 (2), 255.

  37. Colhoun H.M. et al., Nat. Med., 2024, 30 (7), 2058.

  38. Dankner R. et al. JAMA Netw. Open, 2024, 7 (1), e2350408.

  39. Davies M. et al., JAMA, 2017, 318 (15), 1460.

  40. Davies M. et al., Lancet, 2021, 397 (10278), 971 (studio clinico STEP2)

  41. De Giorgi R. et al., eClinicalMedicine, 2024, 10, DOI:https://doi.org/10.1016/j.eclinm.2024.102726.

  42. Deng Y. Et al., Ther. Adv. Chronic Dis., 2022, 13, 20406223221108064.

  43. Diabetes Canada Clinical Practice Guidelines Expert Committee, 2020, 44 (7), P575.

  44. European Medicine Agency − EMA, Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23−26 October 2023 − GLP−1 receptor agonists: available evidence not supporting link with thyroid cancer, 2023, 27 October https://www.ema.europa.eu/en/news/meeting−highlights−pharmacovigilance−risk−assessment−committee−prac−23−26−october−2023 (accesso: luglio 2024)

  45. European Medicine Agency − EMA, Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8−11 April 2024 − GLP−1 receptor agonists: available evidence not supporting link with suicidal and self−injurious thoughts and actions, 2024, 12 April https://www.ema.europa.eu/en/news/meeting−highlights−pharmacovigilance−risk−assessment−committee−prac−8−11−april−2024 (accesso: luglio 2024).

  46. European Medicine Agency − EMA, Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8−11 July 2024 − New recommendations for GLP−1 receptor agonists to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation, 2024a, 12 July https://www.ema.europa.eu/en/news/meeting−highlights−pharmacovigilance−risk−assessment−committee−prac−8−11−july−2024 (accesso: luglio 2024).

  47. Food and Drug Administration − FDA, Ozempic − Full Prescribing Information, 2023, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf (accesso: luglio 2024).

  48. Food and Drug Administration − FDA, FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight, 2024, March 08 https://www.fda.gov/news−events/press−announcements/fda−approves−first−treatment−reduce−risk−serious−heart−problems−specifically−adults−obesity−or (accesso: luglio 2024).

  49. Food and Drug Administration − FDA, Drug Safety Comunication − Update on FDA´s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity, 2024a, 1 November https://www.fda.gov/drugs/drug−safety−and−availability/update−fdas−ongoing−evaluation−reports−suicidal−thoughts−or−actions−patients−taking−certain−type (accesso: luglio 2024).

  50. Food and Drug Administration − FDA, FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, 2024b, 26 July, https://www.fda.gov/drugs/human−drug−compounding/fda−alerts−health−care−providers−compounders−and−patients−dosing−errors−associated−compounded (accesso: settembre 2024).

  51. Frías J.P. et al., NEJM, 2021, 385 (6), 503.

  52. Friedrichsen M. et al., Diabetes Obes. Metab., 2021, 23 (3), 754.

  53. Fuentes B. et al., Neurologia (Engl. Ed.), 2021, 36 (4), 305.

  54. Garber A.J. et al., Endocr. Pract., 2020, 26 (1), 107.

  55. Garvey W.T. et al., Nat. med., 2022, 28 (10), 2083 (studio clinic STEP 5).

  56. Gladstone D.J. et al., Can. J. Neurol. Sci., 2022, 49 (3), 315.

  57. Goldenberg R.M. et al., 2022, Stroke, 53 (5), 1813.

  58. Granhall C. et al., Clin. Pharmacokinet., 2018, 57 (12), 1571.

  59. Guhsn W. et al., eClinicalMedicine, 2024, 72, 102625.

  60. Hacula M. et al., Phamaceuticals (Basel), 2023, 16 (9), 1190.

  61. Hall K.D., Obesity (Silver Spring), 2024, 32 (6), 1163.

  62. Handelsman Y. et al., J. Diabetes Complications, 2022, 36 (2), 108101.

  63. Hathaway J.T. et al., JAMA Ophthalmol., 2024, 3, e242296.

  64. Hauge C. et al., Expert. Opin. Drug Metab. Toxicol., 2021, 17 (9), 1139.

  65. Hiramoto B. et al., Am. J. Gastroenterol., 2024, 119 (6), 1126.

  66. Hjerpsted J.B. et al., Diabetes Obes. Metab., 2018, 20 (3), 610.

  67. Hurtado M. et al., Menopause, 2024, 31 (4), 266.

  68. Husain M. et al., NEJM, 2019, 381 (9), 841 (studio clinic PIONEER 6).

  69. Jordy A.B. et al., Clin. Pharmacokinet., 2021, 60 (9), 1171.

  70. Joshi G.P. et al., American Society of Anestesiologists., 2023, June 29 https://www.asahq.org/about−asa/newsroom/news−releases/2023/06/american−society−of−anesthesiologists−consensus−based−guidance−on−preoperative (accesso: liglio 2024).

  71. Kadowaki T. et al., Lancet Diabetes Endocrinol., 2022, 10 (3), 193 (studio clinico STEP 6).

  72. Kahn S.E. et al., Diabetes Care, 2024, 22, dc240491.

  73. Kapitza C. et al., J. Clin. Pharmacol., 2015, 55 (5), 497.

  74. Kellerer M. et al., Diabetes Obes. Metab., 2022, 24 (9), 1788 (studio clinic SUSTAIN 1).

  75. Kleindorfer D.O. et al., Stroke, 52 (7), e364.

  76. Knop F.K. et al., Lancet, 2023, 402 (10403), 705 (studio clinico OASIS 1).

  77. Kosiborod M.N. et al., NEJM, 2023, 389 (12), 1069 (studio clinico STEP−HfpEF).

  78. Kosiborod M.N. et al., NEJM, 2024, 390 (15), 1394 (studio clinico STEP−HfpEF DM).

  79. LactMed, Semaglutide, 2023, 15 September https://www.ncbi.nlm.nih.gov/books/NBK500980/ (accesso: luglio: 2024).

  80. Langeskov E.K., Kristensen K., Pharmacol. Res. Perspect., 2022, 10 (4), e00962.

  81. Lincoff A.M. et al., NEJM, 2023, 389 (24), 2221 (studio clinico SELECT)

  82. Lingvay I. et al., J. Clin. Endocrinol. Metab., 2022, 107 (5), 1461.

  83. LiverTox, Semaglutide, 2019, April 10 https://www.ncbi.nlm.nih.gov/books/NBK548574/ (accesso: luglio 2024).

  84. Maiorino M.I. et al., Cardiovasc. Diabetol., 2021, 20, 210.

  85. Marbury T.C. et al., Clin. Pharmacokinet., 2017, 56 (11), 1381.

  86. Mariam Z., Niazi S.K., Endocrinol. Diabetes Metab., 2024, 7 (1), e462.

  87. Marso S.P. et al., NEJM, 2016, 375 (19), 1834 (studio clinico SUSTAIN 6).

  88. Maya J. et al., Diabetes, 2024, 73 (Supplement 1), 1214−P.

  89. Mir J. et al., Andrologia, 2018, doi: 10.1111/and.12957.

  90. Mosenzon O. et al., Lancet Diabetes Endocrinol., 2019, 7 (7), 515 studio clinico PIONEER 5).

  91. Nauck M.A., Meier J.J., Diabetes Obes. Metab., 2018, 20 Suppl 1, 5.

  92. Nauck M.A., D´Alessio, Cardiovasc. Diabetol., 2022, 21 (1), 169.

  93. Naude J. et al., Int. J. Obes. (Lond.), 2024, 9, doi: 10.1038/s41366−024−01526−2.

  94. NCT056166013, https://www.clinicaltrials.gov/study/NCT05616013?intr=Bimagrumab&rank=1&tab=history (accesso: luglio 2024).

  95. Nunn E. et al., Mol. Metab., 2024, 80, 101880.

  96. Niu K et al., Front Pharmacol., 2024, 15, 1414268.

  97. Overgaard R.V. et al., Cell. Rep. Med., 2021, 2 (9), 100387.

  98. Pasternak B. et al., BMJ, 2024, 385, e078225.

  99. Perkovic V. et al., NEJM, 2024, 391 (2), 109 (studio clinico FLOW).

  100. Pieber T.R. et al., Lancet Diabetes Endocrinol., 2019, 7 (7), 528 (studio clinico PIONEER 7).

  101. Pratley R.E. et al., Lancet Diabetes Endocrinol., 2018, 6 (4), 275 (studio clinico SUSTAIN 7).

  102. Pratley R. et al., Lancet, 2019, 394 (10192), 39 (studio clinico PIONEER 4).

  103. Rodbard H.W. et al., J. Clin. Endocrinol. Metab., 2018, 103 (6), 2291 (studio clinico SUSTAIN 5).

  104. Rodbard H.W. et al., Diabetes Care, 2019, 42, 2272 (studio clinico PIONEER 2).

  105. Rodriguez P.J. et al., JAMA Intern. Med., 2024, doi:10.1001/jamainternmed.2024.2525.

  106. Rosenstock J. et al., JAMA, 2019, 321 (15), 1466 (studio clinico PIONEER 3).

  107. Rubino D. et al., JAMA, 2021, 325 (14), 1414 (studio clinico STEP 4).

  108. Ryan D.H. et al., Nat. Med., 2024, 30 (7), 2049.

  109. Sattar N. et al., Lancet Diabetes Endocrinol., 2021, 9 (10), 653.

  110. Scavo M.P. et al., Int. J. Mol. Sci., 2024, 25 (3), 1493.

  111. Schoretsanitis G. et al., JAMA Netw. Open, 2024, 7 (8), e2423385.

  112. Shah S.J. et al., Eur. Heart J., 2024, 13, ehae322.

  113. Sodhi M. et al., JAMA, 2023, 330 (18), 1795.

  114. Sorli C. et al., Lancet Diabetes Endocrinol., 2017, 5 (4), 251 (studio clinico SUSTAIN 1).

  115. Spain C.V. et al., Clin. Ther., 2016, 38 (7), 1653.

  116. Strain W.D. et al., Diabetologia, 2020, 63, 258)

  117. Tang Y. Et al., Front. Pharmacol., 2022, 13, 1016639.

  118. Tran M.M. et al., J. Am. Acad. Dermatol., 2024, 91 (1), 166.

  119. Ueda P. et al., JAMA Intern. Med., 2024, Sep 3, doi: 10.1001/jamainternmed.2024.4369.

  120. Verma S. et al., J. A,. Coll. Cardiol., 2024, 2024, DOI: 10.1016/j.jacc.2024.06.001.

  121. Vilsboll T. et al., Diabetes Obes. Metab., 2018, 20 (4), 889.

  122. Wadden T.A. et al., JAMA, 325 (14), 1403 (studio clinic STEP 3).

  123. Wang L. et al., JAMA Netw. Open, 2024, 7 (7), e2421305.

  124. Wang W. et al., Nat. Med., 2024a. 30 (1), 168.

  125. Weghhuber D. et al., NEJM, 2022, 387 (24), 2245 (Studio clinico STEP TEENS).

  126. Welk B. et al., Diabetes Obes. Metab., 2024, 11, doi: 10.1111/dom.15711.

  127. Wilding J.P.H. et al., NEJM, 2021, 384 (11), 989 (studio clinico STEP 1).

  128. Wilding J.P.J. et al., Diabetes Obes. Metab., 2022, 24 (8), 1553 (estensione STEP−1)

  129. World health Organization − WHO, Obesity and Overweight, 2021 https://www.who.int/news−room/fact−sheets/detail/obesity−and−overweight (accesso: giugno 2024).

  130. Wu F. et al., Can. J. Anaesth., 2024, 14, doi: 10.1007/s12630−024−02719−z.

  131. Yabe D. et al., Lancet Diabetes Endocrinol., 2020, 8 (5), 392 (studio clinic PIONEER 10).

  132. Yamada Y. et al., Lancet Diabetes Endocrinol., 2020, 8 (5), 377 (studio clinic PIONEER 9).

  133. Yang Z. et al., Front. Pharmacol., 2022, 13, 925377.

  134. Zhou L et al., BMC Endocr. Disord., 2023, 23 (1), 245.

  135. Zinman B. et al., Diabetes Care, 2019, 42, 2262 (studio clinico PIONEER 8).

  136. Zinman B. et al., Lancet Diabetes Endocrinol., 2019a, 7 (5), 356 (studio clinico SUSTAIN 9).